Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

Unmasking the Hidden Risk: Testing and Diagnosis

At a Glance

CPVT is primarily diagnosed through an Exercise Stress Test, as resting ECGs are typically completely normal. Doctors look for specific abnormal heart rhythms triggered by adrenaline. Genetic testing for RYR2 and CASQ2 genes helps confirm the diagnosis and identify at-risk family members.

Diagnosing Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a unique challenge because the heart usually appears perfectly healthy on standard medical tests. This “hidden” nature can be frightening, as it often leads to a false sense of security before the correct tests are performed [1][2].

Return to the Home Page.

The Deceptive Resting ECG

In most heart conditions, a resting ECG (electrocardiogram) provides the first clues. However, in CPVT, the resting ECG is typically normal [3][4]. This is because the genetic mutations in CPVT affect how the heart handles calcium during stress, not how it functions at rest [4][5].

A normal resting ECG does not rule out CPVT. In some cases, a doctor might notice a slightly slow resting heart rate (sinus bradycardia), but this is often subtle and can be mistaken for high physical fitness [6].

Unmasking the Condition: The Exercise Stress Test (EST)

The “gold standard” for diagnosing CPVT is the Exercise Stress Test (EST) [7][8]. Because CPVT is triggered by adrenaline, the goal is to safely monitor the heart while it is under physical stress.

During the test, doctors look for a very specific progression of heart rhythm changes as the patient’s heart rate increases [9][10]:

  1. PVCs (Premature Ventricular Contractions): Single “extra” beats from the bottom chambers of the heart.
  2. Bigeminy: A pattern where every other beat is an extra beat.
  3. Bidirectional VT: A highly specific, dangerous rhythm where the electrical signal seems to “flip-flop” back and forth. This is a hallmark sign of CPVT [10][11].

If a standard exercise test is inconclusive but symptoms are strong, a doctor may use a Burst Exercise Test, which involves a sudden, high-intensity start to more quickly trigger the adrenaline response [12][13].

Ambulatory Monitoring

While the EST is the most direct test, doctors may also use a Holter monitor (a wearable ECG) or an Implantable Loop Recorder (ILR) (a small device inserted just under the skin) to track the heart rhythm over days, weeks, or months [4][14]. Capturing a real-world event on one of these devices is often a key part of the diagnostic journey.

Alternatives: Pharmacological Challenges

If a patient is too young or unable to perform an exercise test, doctors may use a pharmacological challenge [11][8]. This involves an infusion of epinephrine (adrenaline) or isoproterenol while closely monitored in a hospital setting [11][15]. These drugs mimic the stress of exercise to see if they provoke the signature CPVT arrhythmias [11].

The Role of Genetic Testing

Genetic testing is a vital tool for confirming a diagnosis and protecting the rest of the family [3][16]. You can read more about specific genes in the Biology of CPVT section.

  • Yield: A mutation is found in about 50% to 87% of people who clinically have the disease [17][18].
  • Common Genes: Most cases involve the RYR2 gene (55–71%) or the CASQ2 gene (16–25%) [17][16].
  • Family Screening: Once a mutation is found, all “first-degree” relatives (parents, siblings, and children) should be tested, even if they have no symptoms [16][19].

A negative genetic test does not mean a patient is “cleared” if their exercise test was abnormal, as they may have a mutation in a gene that science has not yet identified [17].

Ruling Out Other Causes

Before a final diagnosis is made, doctors must ensure the symptoms aren’t caused by a physical abnormality in the heart’s structure. This usually requires an echocardiogram (ultrasound) or a cardiac MRI to confirm the heart muscle and valves are shaped correctly [20][21].

Common questions in this guide

Can I still have CPVT if my resting ECG is normal?
Yes. A resting ECG is typically completely normal in people with CPVT. This is because the genetic mutations associated with the condition affect how the heart handles calcium during physical or emotional stress, not while at rest.
What is the best test for diagnosing CPVT?
The exercise stress test is the gold standard for diagnosing CPVT. It allows doctors to monitor your heart rhythm for specific abnormalities, such as premature ventricular contractions (PVCs) or bidirectional VT, as your heart rate increases during physical activity.
How is CPVT diagnosed if I cannot do an exercise stress test?
If a patient is too young or unable to exercise, doctors can use a pharmacological challenge. This involves administering medications like epinephrine or isoproterenol in a closely monitored hospital setting to mimic the effects of physical stress on the heart.
Does a negative genetic test mean I definitely do not have CPVT?
No. While genetic tests identify known mutations in up to 87% of clinical cases, a negative result does not clear you if your exercise test was abnormal. You may have a mutation in a gene that researchers have not yet discovered.
Why do I need an echocardiogram or cardiac MRI for CPVT?
Doctors use imaging tests like echocardiograms or cardiac MRIs to confirm that the heart muscle and valves are structurally normal. Ruling out physical abnormalities in the heart is a required step before confirming a CPVT diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why was my resting ECG completely normal if I have a life-threatening heart condition?
  2. 2.During the Exercise Stress Test (EST), what specific heart rate triggered the first abnormal extra beats (PVCs)?
  3. 3.Which genes were included in the genetic panel, and how should we interpret a 'Variant of Uncertain Significance' (VUS) if one is found?
  4. 4.Is an echocardiogram or cardiac MRI necessary to formally rule out structural heart disease before confirming CPVT?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    A compound heterozygosity of Tecrl gene confirmed in a catecholaminergic polymorphic ventricular tachycardia family.

    Xie L, Hou C, Jiang X, et al.

    European journal of medical genetics 2019; (62(7)):103631 doi:10.1016/j.ejmg.2019.01.018.

    PMID: 30790670
  2. 2

    Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report.

    Schumer A, Contag S

    Journal of medical case reports 2020; (14(1)):238 doi:10.1186/s13256-020-02569-5.

    PMID: 33292493
  3. 3

    Identification of a novel exon3 deletion of RYR2 in a family with catecholaminergic polymorphic ventricular tachycardia.

    Dharmawan T, Nakajima T, Ohno S, et al.

    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2019; (24(3)):e12623 doi:10.1111/anec.12623.

    PMID: 30615235
  4. 4

    Insights Into the Pathogenesis of Catecholaminergic Polymorphic Ventricular Tachycardia From Engineered Human Heart Tissue.

    Park SJ, Zhang D, Qi Y, et al.

    Circulation 2019; (140(5)):390-404 doi:10.1161/CIRCULATIONAHA.119.039711.

    PMID: 31311300
  5. 5

    Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.

    Wleklinski MJ, Kannankeril PJ, Knollmann BC

    The Journal of physiology 2020; (598(14)):2817-2834 doi:10.1113/JP276757.

    PMID: 32115705
  6. 6

    The evolving role of ankyrin-B in cardiovascular disease.

    Koenig SN, Mohler PJ

    Heart rhythm 2017; (14(12)):1884-1889 doi:10.1016/j.hrthm.2017.07.032.

    PMID: 28765088
  7. 7

    The Purkinje-myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT.

    Blackwell DJ, Faggioni M, Wleklinski MJ, et al.

    JCI insight 2022; (7(3)).

    PMID: 34990403
  8. 8

    Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.

    Vaksmann G, Klug D

    Pacing and clinical electrophysiology : PACE 2018; (41(10)):1378-1380 doi:10.1111/pace.13446.

    PMID: 29989676
  9. 9

    Effects of Catheter Ablation Targeting the Trigger Beats in Inherited Catecholaminergic Polymorphic Ventricular Tachycardia.

    Kaneshiro T, Nogami A, Kato Y, et al.

    JACC. Clinical electrophysiology 2017; (3(9)):1062-1063 doi:10.1016/j.jacep.2017.04.017.

    PMID: 29759714
  10. 10

    Choking-induced cardiac arrest unmasks a diagnosis of catecholaminergic polymorphic ventricular tachycardia.

    Roston TM, AlAhmari L, Krahn AD, et al.

    HeartRhythm case reports 2015; (1(6)):494-497 doi:10.1016/j.hrcr.2015.08.007.

    PMID: 28491614
  11. 11

    Broad and narrow complex tachycardia resulting in cardiorespiratory arrest in a child: what is the optimal treatment strategy?

    Sadagopan SN, Yue AM

    European heart journal. Case reports 2023; (7(10)):ytad490 doi:10.1093/ehjcr/ytad490.

    PMID: 37869737
  12. 12

    Burst Exercise Testing Can Unmask Arrhythmias in Patients With Incompletely Penetrant Catecholaminergic Polymorphic Ventricular Tachycardia.

    Roston TM, Kallas D, Davies B, et al.

    JACC. Clinical electrophysiology 2021; (7(4)):437-441 doi:10.1016/j.jacep.2021.02.013.

    PMID: 33888264
  13. 13

    Athletes and suspected catecholaminergic polymorphic ventricular tachycardia: Awareness and current knowledge.

    Mascia G, Brugada J, Arbelo E, Porto I

    Journal of cardiovascular electrophysiology 2023; (34(10)):2095-2101 doi:10.1111/jce.16045.

    PMID: 37655865
  14. 14

    Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death.

    Walsh R, Adler A, Amin AS, et al.

    European heart journal 2022; (43(15)):1500-1510 doi:10.1093/eurheartj/ehab687.

    PMID: 34557911
  15. 15

    Radiofrequency catheter ablation for drug-refractory atrial tachyarrhythmias in a patient with catecholaminergic polymorphic ventricular tachycardia: A case report.

    Kawada S, Morita H, Watanabe A, Ito H

    Journal of cardiology cases 2019; (19(1)):36-39 doi:10.1016/j.jccase.2018.09.004.

    PMID: 30693058
  16. 16

    BASIC AND CLINICAL INSIGHTS IN CATECHOLAMINERGIC (FAMILIAL) POLYMORPHIC VENTRICULAR TACHYCARDIA.

    Márquez MF, Totomoch-Serra A, Rueda A, et al.

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2019; (71(4)):226-236 doi:10.24875/RIC.19002939.

    PMID: 31448784
  17. 17

    Clinical Characteristics, Genetic Findings and Arrhythmic Outcomes of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia from China: A Systematic Review.

    Leung J, Lee S, Zhou J, et al.

    Life (Basel, Switzerland) 2022; (12(8)) doi:10.3390/life12081104.

    PMID: 35892906
  18. 18

    Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.

    Imberti JF, Underwood K, Mazzanti A, Priori SG

    Heart, lung & circulation 2016; (25(8)):777-83.

    PMID: 26948768
  19. 19

    Impact of cascade screening for catecholaminergic polymorphic ventricular tachycardia type 1.

    Shimamoto K, Ohno S, Kato K, et al.

    Heart (British Cardiac Society) 2022; (108(11)):840-847 doi:10.1136/heartjnl-2021-320220.

    PMID: 35135837
  20. 20

    Catecholaminergic Polymorphic Ventricular Tachycardia - Looking to the Future.

    Velcea AE, Siliste C, Vinereanu D

    Maedica 2017; (12(4)):306-310.

    PMID: 29610596
  21. 21

    Efficacy of bilateral thoracoscopic sympathectomy in a patient with catecholaminergic polymorphic ventricular tachycardia.

    Okajima K, Kiuchi K, Yokoi K, et al.

    Journal of arrhythmia 2016; (32(1)):62-6 doi:10.1016/j.joa.2015.07.002.

    PMID: 26949433

This page provides educational information on CPVT testing and diagnosis. Always consult a cardiologist or electrophysiologist to interpret your specific test results and guide your diagnostic journey.

Get notified when new evidence is published on Catecholaminergic polymorphic ventricular tachycardia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.